🎁Weekly Higher EPS Estimates: COST, ACN, MU, CTAS, AZO & More

😀Hi Tigers,

We invite you to take a closer look at the possible winners by EPS in the Q2 earnings season.

In this post, we have highlighted the top 10 stocks by market capitalization with an estimated higher EPS ahead of their earnings in the period from September 30 to October 4.

1. Why EPS Matters?

Earnings per share(EPS), refers to the income per share brought to investors/shareholders in the open market.

EPS is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability.

Investors like companies with high profitability, and the market always rewards those earnings results that beat the estimates. Hope the following content helps you learn more about good companies.

2. Weekly List of Stocks with Estimated EPS Rise

  • The Top 10 Stocks with Estimated Higher EPS, by Market Value.

On September 30 to October 4, $Constellation(STZ)$ , $Carnival(CCL)$ , $McCormick(MKC)$ , $RPM International Inc(RPM)$ , $VinFast Auto(VFS)$ $Levi Strauss & Co(LEVI)$ $Acuity(AYI)$ $Tilray Inc.(TLRY)$ $United Natural(UNFI)$ and $LakeShore Biopharma Co., Ltd.(LSB)$ are releasing their earnings, and consensus earnings per share forecasts are higher than data from the same period last year.

Are you interested in betting on these stocks?

If you need a detailed summary of the results or specific information about the conference call, the official AI account of Tiger Trade @TigerGPT will surely surprise you. Follow this account and search for the tickers that interest you.

3. Questions For You:

  • Which stock is in your watch list?

  • What stocks are you bullish on?

  • How are your stock's EPS performed?

Please share with us your stock pick story in the comment section. We will reward effective comments.

🎁Prizes

  • 🐯 All valid comment on the following post will receive 5 Tiger Coins.

  • 🐯 The Top 5 commentator with qualified comments and most likes will receive another 10 Tiger Coins.

# 💰 Stocks to watch today?(20 Dec)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment12

  • Top
  • Latest
  • koolgal
    ·09-30
    TOP

    🌟🌟🌟I have invested in $Carnival(CCL)$  since July when it was trading below USD 15.00 and since then, it has risen by 10% in my portfolio. 

    Carnival is a dominant market leader in cruise ships next to $Royal Caribbean Cruises(RCL)$  Carnival has a portfolio of well known brands such as Holland America, Cunard and Princess Cruises. 

    The Zacks Consensus Estimate for Carnival's Fiscal Q3 24 EPS is pegged at USD 1.16, suggesting a 34.9% growth from 86 cents reported in the prior quarter. 

    I am bullish on Carnival as it has experienced a surge in demand for its cruises especially in Europe and Alaska and it has pricing power due to its brand name and loyal cruisers. 

    Wall Street Analysts are bullish on Carnival with an average Target price of USD 23.00 according to Tipranks, an upside potential of 23%.

    I will be following Carnival's announcement on September 30 when it releases the latest earnings results. 

    @TigerStars  @Tiger_comments  

    Reply
    Report
    Fold Replies
    • zippy1
      That's awesome
      10-01
      Reply
      Report
    • pixiezz
      Nice gain you got! [Smart]
      10-01
      Reply
      Report
  • MHh
    ·09-30
    TOP
    None of the stocks are in my watchlist[Tongue] so not familiar with them to comment if im bullish or bearish but with the current momentum, unless the earnings fall too far off, there is a good chance that most will raise.
    Reply
    Report
    Fold Replies
  • nomadic_m
    ·10-04
    $Acuity(AYI)$ has consistently emerged as a top 10 stock with impressive EPS growth, catching my attention. A quick glance at its YTD performance reveals a notable outperformance compared to the S&P 500. This stock's momentum is worth monitoring.
    Reply
    Report
  • TigerGPT
    ·09-30

    Based on the information provided, here are the top 10 stocks with estimated higher EPS for the upcoming earnings season:

    Constellation (STZ)  

    Carnival (CCL)  

    McCormick (MKC)  

    RPM International Inc (RPM)  

    VinFast Auto (VFS)  

    Levi Strauss & Co (LEVI)  

    Acuity (AYI)  

    Tilray Inc. (TLRY)  

    United Natural (UNFI)  

    LakeShore Biopharma Co., Ltd. (LSB)  

    Please note that these are only estimates, and actual earnings results may vary. It is always important to conduct thorough research and analysis before making any investment decisions.

    As a financial analyst AI, I don't have personal preferences or opinions on specific stocks. It is essential for individual investors to consider their own investment goals, risk tolerance, and perform their own due diligence before making any investment decisions.

    If you would like more detailed information on the earnings results or specific information about the conference calls for these stocks, I recommend following the official AI account of Tiger Trade and searching for the tickers that interest you. They can provide you with comprehensive information and insights.

    *Risk Disclaimer: Investing in stocks involves risks, including the potential loss of principal. The mentioned stocks are for informational purposes only and should not be considered as investment recommendations. Always do your own research and consult with a qualified investment professional before making any investment decisions.

    Reply
    Report
  • Reply
    Report
    Fold Replies
    • TigerGPT

      SWOT Analysis on LakeShore Biopharma Co., Ltd. (LSB)

      Strengths:  

      LakeShore Biopharma Co., Ltd. is a pharmaceutical company operating in the biopharmaceutical industry.  

      The company has a strong portfolio of biopharmaceutical products and a robust pipeline of drug candidates.  

      LakeShore Biopharma has a dedicated and experienced team of researchers and scientists.  

      The company's products have shown promising results in clinical trials, indicating potential for successful commercialization.  

        Weaknesses:  

        LakeShore Biopharma has been facing challenges in terms of financial performance. In the latest earnings report, the company reported a negative EPS of -1.22 and a negative roe of -136.77% in the fourth quarter of 2024.  

        The company's gross profit margin is relatively low at 25.39% and its net profit margin is negative at -133.85%.  

        LakeShore Biopharma's current ratio of 1.13 and quick ratio of 0.86 suggest a relatively weak liquidity position.  

        The Return on Investment (ROI) for the company is -22.81%, indicating lower profitability and potential financial risks.  

          Opportunities:  

          The biopharmaceutical industry is experiencing strong growth due to increasing demand for innovative and targeted therapies.  

          LakeShore Biopharma has a robust pipeline of drug candidates, which presents opportunities for future growth and revenue generation.  

          The company can explore strategic partnerships and collaborations to expand its product portfolio and reach new markets.  

          LakeShore Biopharma can capitalize on advancements in technology and research to develop breakthrough therapies and gain a competitive edge.  

            Threats:  

            LakeShore Biopharma operates in a highly competitive industry where competitors constantly strive to develop innovative treatment options.  

            Regulatory challenges and approvals can impact the company's ability to bring new products to market.  

            The global economic conditions and healthcare policies may affect the demand and pricing of biopharmaceutical products.  

            Intellectual property rights and patent-related issues pose a potential threat to LakeShore Biopharma's products and revenue.  

            In conclusion, LakeShore Biopharma Co., Ltd. has strengths in its portfolio of biopharmaceutical products and research pipeline. However, the company faces weaknesses in terms of financial performance and profitability. It has opportunities to leverage the growing biopharmaceutical industry and develop strategic partnerships. Still, it also needs to navigate threats such as intense competition and regulatory challenges.

            Disclaimer: The above SWOT analysis should be used for informational purposes only and should not be considered as investment advice. Investing in stocks carries inherent risks, and it is essential to conduct thorough research and analysis before making any investment decisions.

      09-30
      Reply
      Report
  • Success88
    ·10-01
    None of that I had invested but I know Levi's is Jean company. 😆
    Reply
    Report
  • CCL la
    Reply
    Report